OnKure Therapeutics, Inc. cotiza a 2.35 USD y tiene una capitalización bursátil de $95M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) h…
| Periodo | 2026-08 | 2026-05 | 2026-03 | 2025-11 |
|---|---|---|---|---|
| Real | $-0.31 | $-1.11 | $-0.99 | $-1.09 |
| Estimado | $-0.53 | $-0.74 | $-1.15 | $-1.20 |
| Sorpresa | +41.5% | -50.0% | +13.9% | +9.2% |
| Métrica | OKUR | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -105.9% | -40.4% | -65.5% |
| ROA | -95.8% | -32.0% | -63.8% |
| Current Ratio | 10.28 | 2.84 | +7.44 |
| Debt / Equity | — | 0.28 | — |